» Articles » PMID: 24386988

Adherence to Artemisinin-based Combination Therapy for the Treatment of Malaria: a Systematic Review of the Evidence

Overview
Journal Malar J
Publisher Biomed Central
Specialty Tropical Medicine
Date 2014 Jan 7
PMID 24386988
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increasing access to and targeting of artemisinin-based combination therapy (ACT) is a key component of malaria control programmes. To maximize efficacy of ACT and ensure adequate treatment outcomes, patient and caregiver adherence to treatment guidelines is essential. This review summarizes the current evidence base on ACT adherence, including definitions, measurement methods, and associated factors.

Methods: A systematic search of the published literature was undertaken in November 2012 and updated in April 2013. Bibliographies of manuscripts were also searched and additional references identified. Studies were included if they involved at least one form of ACT and reported an adherence measurement.

Results: The search yielded 1,412 records, 37 of which were found to measure adherence to ACT. Methods to measure adherence focused on self-report, pill counts and bioassays with varying definitions for adherence. Most studies only reported whether medication regimens were completed, but did not assess how the treatment was taken by the patient (i.e. timing, frequency and dose). Adherence data were available for four different ACT formulations: artemether-lumefantrine (AL) (range 39-100%), amodiaquine plus artesunate (AQ + AS) (range 48-94%), artesunate plus sulphadoxine-pyrimethamine (AS + SP) (range 39-75%) and artesunate plus mefloquine (AS + MQ) (range 77-95%). Association between demographic factors, such as age, gender, education and socio-economic status and adherence to ACT regimens was not consistent. Some evidence of positive association between adherence and patient age, caregiver education levels, drug preferences, health worker instructions, patient/caregiver knowledge and drug packaging were also observed.

Conclusions: This review highlights the weak evidence base on ACT adherence. Results suggest that ACT adherence levels varied substantially between study populations, but comparison between studies was challenging due to differences in study design, definitions, and methods used to measure adherence. Standardising methodologies for both self-report and bioassays used for evaluating adherence of different formulations across diverse contexts would improve the evidence base on ACT adherence and effectiveness; namely, specific and measurable definitions for adherence are needed for both methodologies. Additionally, further studies of the individual factors and barriers associated with non-adherence to ACT are needed in order to make informed policy choices and to improve the delivery of effective malaria treatment.

Citing Articles

A mixed methods study investigating factors affecting adherence to Plasmodium vivax malaria primaquine radical cure regimens among migrants along the Myanmar-Thailand border.

Ansari A, Aung K, Win H, Beau C, Nu B, Soe N PLOS Glob Public Health. 2025; 5(1):e0003615.

PMID: 39820011 PMC: 11737701. DOI: 10.1371/journal.pgph.0003615.


"If they take it without knowing, they will default…": perceptions of targeted information transfer to promote adherence to intermittent preventive treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy in western....

Hoyt J, Barsosio H, Odero I, Omondi B, Achieng F, Kariuki S Malar J. 2024; 23(1):364.

PMID: 39614335 PMC: 11605956. DOI: 10.1186/s12936-024-05131-6.


Adapting malaria indicator surveys to investigate treatment adherence: a pilot study on Bioko Island, Equatorial Guinea.

Galick D, Donfack O, Mifumu T, Onvogo C, Dougan T, Mikue M Malar J. 2024; 23(1):244.

PMID: 39138464 PMC: 11323597. DOI: 10.1186/s12936-024-05057-z.


Medication adherence framework: A population-based pharmacokinetic approach and its application in antimalarial treatment assessments.

Ding J, Hoglund R, Tarning J CPT Pharmacometrics Syst Pharmacol. 2024; 13(5):795-811.

PMID: 38528724 PMC: 11098161. DOI: 10.1002/psp4.13119.


Adherence to Anti-Malarial Treatment in Malaria Endemic Areas of Bangladesh.

Hossain M, Matin M, Ferdous N, Hasan A, Sazed S, Neogi A Pathogens. 2023; 12(12).

PMID: 38133277 PMC: 10745796. DOI: 10.3390/pathogens12121392.


References
1.
Whitty C, Chandler C, Ansah E, Leslie T, Staedke S . Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J. 2008; 7 Suppl 1:S7. PMC: 2604871. DOI: 10.1186/1475-2875-7-S1-S7. View

2.
von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

3.
Le N, Pham T, Nguyen B, Dang C, Pham T, Le D . Efficacy and effectiveness of five day treatment of uncomplicated falciparum with artemisinin or artesunate in Vietnam. Southeast Asian J Trop Med Public Health. 2000; 30(1):3-6. View

4.
Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J . Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg. 2004; 71(5):525-30. View

5.
Faucher J, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B . Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis. 2009; 200(1):57-65. DOI: 10.1086/599378. View